Kala Pharmaceuticals stock rockets nearly 300% after FDA OKs IND application for PCED treatment

Shares of Kala Pharmaceuticals Inc. KALA, quadrupled in very volatile trading Wednesday, after the biopharmaceutical company said the Food and Drug Administration accepted its investigational new drug (IND) application for KPI-012, its treatment of persistent corneal epithelial defect (PCED). With…#kpi012 #kala #spx
Source: Reuters: Health - Category: Consumer Health News Source Type: news